You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Patent: 11,072,615


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,072,615
Title:Solid forms of a toll-like receptor modulator
Abstract:The present invention provides crystalline forms, solvates and hydrates of 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one, and methods of making.
Inventor(s):Brown Brandon Heath, Roethle Paul A.
Assignee:GILEAD SCIENCES, INC.
Application Number:US16678788
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 11,072,615

Introduction

When analyzing a patent, particularly one like United States Patent 11,072,615, it is crucial to delve into the specifics of the claims, the broader patent landscape, and the legal frameworks that govern patent eligibility. This analysis will cover the key aspects of patent-eligible subject matter, the Alice/Mayo framework, and the implications of recent judicial and administrative developments.

Understanding Patent-Eligible Subject Matter

Patent-eligible subject matter is defined under Section 101 of the Patent Act (35 U.S.C. §101), which allows for the patenting of "any new and useful process, machine, manufacture, or composition of matter"[1].

The Alice/Mayo Framework

The Supreme Court's decisions in Alice Corp. Pty. v. CLS Bank and Mayo Collaborative Servs. v. Prometheus Labs. established the two-step Alice/Mayo test for determining patent-eligible subject matter.

Step One: Identifying Ineligible Concepts

The first step involves determining whether the patent claims are "directed to" an ineligible concept, such as a law of nature, a natural phenomenon, or an abstract idea. If the claims are not directed to an ineligible concept, they are considered patent-eligible[1][2].

Step Two: Searching for an Inventive Concept

If the claims are directed to an ineligible concept, the second step evaluates whether the claims contain an inventive concept that transforms the nature of the claim into a patent-eligible application. This involves examining the elements of each claim, both individually and as an ordered combination, to see if they add anything significant beyond the ineligible concept itself[1][2].

Case Study: Trinity Info Media, LLC v. Covalent, Inc.

In the case of Trinity Info Media, LLC v. Covalent, Inc., the court applied the Alice/Mayo framework to determine that the asserted patents did not claim patentable subject matter under 35 U.S.C. §101. The patents related to methods and systems for connecting users based on their answers to polling questions, which were deemed to be abstract ideas without an inventive concept[2].

Implications for Patent 11,072,615

To analyze the claims of United States Patent 11,072,615, one must apply the Alice/Mayo framework rigorously.

Claim Construction and Analysis

  • Step One: Determine if the claims are directed to an abstract idea, law of nature, or natural phenomenon.
  • Step Two: If so, evaluate whether the claims include an inventive concept that goes beyond the ineligible concept.

Example Analysis

If Patent 11,072,615 involves claims related to software or business methods, it is crucial to assess whether these claims are merely abstract ideas implemented on a generic computer or if they include specific, inventive elements that transform the claim into a patent-eligible application.

Stakeholder Views and Recent Developments

Stakeholders have varying opinions on the impact of the Alice/Mayo framework on innovation and investment in technology. The USPTO's 2019 Guidance aimed to clarify how to apply the Alice/Mayo framework, particularly for AI-related inventions, and has been seen as lowering barriers to patentability for computer-related inventions[1].

Judicial and Administrative Guidance

The USPTO's guidance, while not binding on courts, has influenced the review of patent applications. However, court decisions remain the final arbiter, and the lack of consistency between USPTO guidance and judicial rulings can create uncertainty for patent applicants[1].

The Role of AI in Patent Analysis

AI techniques are increasingly being used to analyze patent claims, including determining indefiniteness under 35 U.S.C. §112(b). AI can help in identifying whether claims are sufficiently clear and definite to inform those skilled in the art about the scope of the invention[5].

Drafting Patent Applications

A well-written patent application must describe the invention so that one of ordinary skill can understand and replicate it. Claims must be clear, distinct, and particularly point out the subject matter of the invention. Avoiding overly narrow characterizations and ensuring that claims are neither too broad nor too narrow is essential[4].

Conclusion

Analyzing the claims of United States Patent 11,072,615 requires a thorough understanding of the Alice/Mayo framework and the broader legal landscape governing patent eligibility. The application of this framework, combined with recent judicial and administrative developments, is crucial for determining the validity and scope of patent claims.

Key Takeaways

  • Patent-Eligible Subject Matter: Defined under Section 101 of the Patent Act, it includes processes, machines, manufactures, and compositions of matter.
  • Alice/Mayo Framework: A two-step test to determine if claims are directed to ineligible concepts and if they contain an inventive concept.
  • Judicial and Administrative Guidance: Recent decisions and USPTO guidance impact the patentability of software, business methods, and AI-related inventions.
  • AI in Patent Analysis: AI can assist in analyzing claim definiteness and other legal aspects of patent claims.
  • Drafting Patent Applications: Clear, distinct claims and thorough descriptions are essential for a valid patent application.

FAQs

Q1: What is the Alice/Mayo framework, and how does it impact patent eligibility? The Alice/Mayo framework is a two-step test established by the Supreme Court to determine if patent claims are directed to ineligible concepts (like abstract ideas) and if they contain an inventive concept that makes them patent-eligible.

Q2: How has the USPTO's 2019 Guidance affected the patentability of AI-related inventions? The USPTO's 2019 Guidance has been perceived as lowering barriers to patentability for AI-related and computer-related inventions by clarifying how to apply the Alice/Mayo framework, leading to an increase in the allowance rate for such patent applications.

Q3: What are the key elements of a well-written patent application? A well-written patent application must describe the invention clearly, provide distinct and definite claims, disclose the best mode of the invention, and ensure that claims are neither too broad nor too narrow.

Q4: How does AI assist in patent analysis? AI can assist in analyzing patent claims by helping to determine indefiniteness, identifying whether claims are clear and distinct, and supporting the decision-making process in patent eligibility assessments.

Q5: What are the implications of the Trinity Info Media, LLC v. Covalent, Inc. case for patent claims? The case highlights that claims directed to abstract ideas without an inventive concept are not patentable under 35 U.S.C. §101, emphasizing the importance of applying the Alice/Mayo framework rigorously.

Sources

  1. Congressional Research Service. Patent-Eligible Subject Matter Reform: An Overview. January 3, 2024.
  2. United States Court of Appeals for the Federal Circuit. Trinity Info Media, LLC v. Covalent, Inc. July 14, 2023.
  3. Patently-O. Damages Experts Analysis on the Front Burner. November 12, 2024.
  4. United States Patent and Trademark Office. Drafting a Provisional Application. June 5, 2013.
  5. Indiana University Maurer School of Law. Using AI to Analyze Patent Claim Indefiniteness.

More… ↓

⤷  Subscribe

Details for Patent 11,072,615

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 11,072,615 2039-11-08
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 11,072,615 2039-11-08
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 11,072,615 2039-11-08
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 11,072,615 2039-11-08
Merck Sharp & Dohme Llc RECOMBIVAX, RECOMBIVAX HB hepatitis b vaccine (recombinant) Injection 101066 July 23, 1986 11,072,615 2039-11-08
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 June 04, 1986 11,072,615 2039-11-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.